AZ sells ex-US rights to old cancer drugs Arimidex and Casod...

For several years AstraZeneca has been selling off rights to its older drugs to raise cash as it develops a new generation of drugs, and this pattern has continued as it sold its Arimidex a

Xtandi catches up with Erleada in castration-sensitive prost...

Merck & Co's Keytruda shows promise with prostate cancer 'su...

A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super responders’ to Merck & Co’s Keytruda (pembrolizumab) immunotherapy i

FDA approves J&J's prostate cancer drug Erleada in new use, ...

The FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has spread.

AZ/MSD’s Lynparza sees positive results in prostate cancer

AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).

Bayer aims at J&J and Pfizer with new prostate cancer drug

The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.